US 11,905,537 B2
Bifunction chemical epigenetic modifiers and methods of use
Nate Hathaway, Chapel Hill, NC (US); Jian Jin, New York, NY (US); Kyle Butler, Salt Lake City, UT (US); and Anna Chiarella, Chapel Hill, NC (US)
Assigned to THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, NC (US)
Appl. No. 16/636,464
Filed by The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
PCT Filed Aug. 3, 2018, PCT No. PCT/US2018/045266
§ 371(c)(1), (2) Date Feb. 4, 2020,
PCT Pub. No. WO2019/028426, PCT Pub. Date Feb. 7, 2019.
Claims priority of provisional application 62/654,958, filed on Apr. 9, 2018.
Claims priority of provisional application 62/541,343, filed on Aug. 4, 2017.
Prior Publication US 2021/0355476 A1, Nov. 18, 2021
Int. Cl. C12N 9/90 (2006.01); A61K 47/55 (2017.01); A61K 31/167 (2006.01); A61K 31/436 (2006.01); A61K 38/15 (2006.01); C07K 14/47 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01)
CPC C12N 9/90 (2013.01) [A61K 31/167 (2013.01); A61K 31/436 (2013.01); A61K 38/15 (2013.01); A61K 47/55 (2017.08); C07K 14/4702 (2013.01); C12N 9/22 (2013.01); C12N 15/111 (2013.01); C12N 2310/20 (2017.05)] 8 Claims
 
1. A bifunctional chemical epigenetic modifier (CEM) comprising a molecule of FK506 or derivative thereof, a linker and a histone deacetylase inhibitor, wherein the histone deacetylase inhibitor is suberanilohydroxamic acid, depsipeptide or a derivative thereof.